Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

Impact · against what's priced in

Guardant Health sees a significant near-term catalyst in UnitedHealth Group's broad coverage of the Shield test and a clear path to margin expansion via COGS reductions. While the absence of other major payer decisions through 2026 limits the immediate ceiling, the growth in MRD and oncology testing indicates strong product-market fit.

GH+0.70: No priced-in read yet

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

What matters in this story

AstraZeneca: 3 Key Takeaways for Long-Term Investors

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

What matters in this story

AstraZeneca: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Connected tickers

Track these names every morning.

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

OmniAb: A Self-Funding Option Book On 433 Partner Programs

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

What matters in this story

Next reads from the same story arc

AstraZeneca: 3 Key Takeaways for Long-Term Investors

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

What matters in this story

Next reads from the same story arc

AstraZeneca: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Connected tickers

Track these names every morning.

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

OmniAb: A Self-Funding Option Book On 433 Partner Programs

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX